New drug cocktail shows early promise for Hard-to-Treat myeloma

NCT ID NCT03702725

Completed Disease control Sponsor: Alliance Foundation Trials, LLC. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a combination of three drugs—ibrutinib, lenalidomide, and dexamethasone—in 14 people with multiple myeloma that had come back or stopped responding to prior treatments. The main goal was to find safe doses and watch for side effects. Results help guide future research on whether this combo can better control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ibrutinib (Imbruvica) combined with lenalidomide (Revlimid) and dexamethasone (Decadron)
What this could lead to: If this combination proves safe and effective, it could offer a new treatment option for people with multiple myeloma that has returned or stopped responding to therapy.
What could go wrong: This is a very early phase 1 trial with only 14 participants, so safety and dosing are still being figured out. The combination may cause serious side effects like low blood counts or blood clots, and it is too soon to know if it truly helps control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA MULTIPLE MYELOMA IN RELAPSE REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Loyola University Medical Center

Maywood, Illinois, 60153, United States
Rhode Island Hospital

Providence, Rhode Island, 02903, United States
The Ohio State University Wexner Medical Center/James Cancer Hospital

Columbus, Ohio, 43210, United States
Wake Forest Baptist Comprehensive Cancer Center

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.